

Orbifloxacin / Posaconazole / Mometasone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
6.0	03.12.2024	439121-00019	Date of first issue: 06.01.2016

SECTION 1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Orbifloxacin / Posaconazole / Mometasone Formulation

Manufacturer or supplier's details

Company name of supplier : MSD
Address : 126 E. Lincoln Avenue
Rahway, New Jersey U.S.A. 07065
Telephone : 908-740-4000
Emergency telephone : 1-908-423-6000
E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product
Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION**GHS Classification**

Serious eye damage/eye irritation : Category 2B

Reproductive toxicity : Category 1B

GHS label elements

Hazard pictograms :



Signal Word : Danger

Hazard Statements : H320 Causes eye irritation.
H360Df May damage the unborn child. Suspected of damaging fertility.

Precautionary Statements : **Prevention:**
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P264 Wash skin thoroughly after handling.
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.
Response:
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P308 + P313 IF exposed or concerned: Get medical advice/ attention.

**Orbifloxacin / Posaconazole / Mometasone
Formulation**

Version 6.0	Revision Date: 03.12.2024	SDS Number: 439121-00019	Date of last issue: 30.09.2023 Date of first issue: 06.01.2016
----------------	------------------------------	-----------------------------	-------------------------------------------------------------------

P337 + P313 If eye irritation persists: Get medical advice/ attention.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards

None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
White mineral oil (petroleum)	8042-47-5	≥ 50 -< 70
Orbifloxacin	113617-63-3	≥ 1 -< 5
Posaconazole	171228-49-2	≥ 0.1 -< 1
Mometasone	83919-23-7	≥ 0.1 -< 1

SECTION 4. FIRST AID MEASURES

General advice	: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.
If inhaled	: If inhaled, remove to fresh air. Get medical attention.
In case of skin contact	: In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.
In case of eye contact	: In case of contact, immediately flush eyes with plenty of water for at least 15 minutes. If easy to do, remove contact lens, if worn. Get medical attention.
If swallowed	: If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.
Most important symptoms and effects, both acute and delayed	: Causes eye irritation. May damage the unborn child. Suspected of damaging fertility.
Protection of first-aiders	: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
Notes to physician	: Treat symptomatically and supportively.

**Orbifloxacin / Posaconazole / Mometasone
Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
6.0	03.12.2024	439121-00019	Date of first issue: 06.01.2016

SECTION 5. FIRE-FIGHTING MEASURES

- Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical
- Unsuitable extinguishing media : None known.
- Specific hazards during fire fighting : Exposure to combustion products may be a hazard to health.
- Hazardous combustion products : Carbon oxides
- Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.
- Special protective equipment for fire-fighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

- Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
- Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Prevent spreading over a wide area (e.g., by containment or oil barriers).
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.
- Methods and materials for containment and cleaning up : Soak up with inert absorbent material.
For large spills, provide diking or other appropriate containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate container.
Clean up remaining materials from spill with suitable absorbent.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.

**Orbifloxacin / Posaconazole / Mometasone
Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
6.0	03.12.2024	439121-00019	Date of first issue: 06.01.2016

Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

- Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
- Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.
- Advice on safe handling : Do not get on skin or clothing.
Do not breathe vapors or spray mist.
Do not swallow.
Do not get in eyes.
Wash skin thoroughly after handling.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Keep container tightly closed.
Take care to prevent spills, waste and minimize release to the environment.
- Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.
- Conditions for safe storage : Keep in properly labeled containers.
Keep tightly closed.
Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:
Strong oxidizing agents
Self-reactive substances and mixtures
Organic peroxides
Explosives
Gases

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION**Ingredients with workplace control parameters**

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
White mineral oil (petroleum)	8042-47-5	VLE-PPT (Mist)	5 mg/m ³	NOM-010-STPS-2014
		TWA (Inhalable particulate)	5 mg/m ³	ACGIH

**Orbifloxacin / Posaconazole / Mometasone
Formulation**

Version 6.0 Revision Date: 03.12.2024 SDS Number: 439121-00019 Date of last issue: 30.09.2023
Date of first issue: 06.01.2016

		matter)		
Orbifloxacin	113617-63-3	TWA	0.2 mg/m ³ (OEB 2)	Internal
Posaconazole	171228-49-2	TWA	300 µg/m ³ (OEB 2)	Internal
Mometasone	83919-23-7	TWA	1 µg/m ³ (OEB 4)	Internal
Further information: Skin				
		Wipe limit	10 µg/100 cm ²	Internal

Engineering measures : The information below is intended for larger pilot/commercial-scale operations and manufacturing. For smaller scale, clinical, or pharmacy settings, site-specific internal risk assessment practices should be conducted to determine appropriate exposure control measures. The health hazard risks of handling this material are dependent on multiple factors, including but not limited to physical form and quantity handled. If applicable, use process enclosures, local exhaust ventilation (e.g., Biosafety Cabinet, Ventilated Balance Enclosures), or other engineering controls to maintain airborne levels below recommended exposure limits. If exposure limits have not been established, maintain airborne levels as low as reasonably achievable. All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Essentially no open handling permitted. Use closed processing systems or containment technologies. If handled in a laboratory, use a properly designed biosafety cabinet, fume hood, or other containment device if the potential exists for aerosolization. If this potential does not exist, handle over lined trays or benchtops.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Combined particulates and organic vapor type

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection : Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially

**Orbifloxacin / Posaconazole / Mometasone
Formulation**

Version 6.0	Revision Date: 03.12.2024	SDS Number: 439121-00019	Date of last issue: 30.09.2023 Date of first issue: 06.01.2016
----------------	------------------------------	-----------------------------	-------------------------------------------------------------------

contaminated clothing.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	:	suspension
Color	:	white to off-white
Odor	:	odorless
Odor Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	No data available
Evaporation rate	:	No data available
Flammability (solid, gas)	:	Not applicable
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapor pressure	:	No data available
Relative vapor density	:	No data available
Relative density	:	No data available
Density	:	No data available
Solubility(ies) Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	Not applicable
Autoignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive

**Orbifloxacin / Posaconazole / Mometasone
Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
6.0	03.12.2024	439121-00019	Date of first issue: 06.01.2016

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Particle characteristics
Particle size : Not applicable

SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.
Chemical stability : Stable under normal conditions.
Possibility of hazardous reactions : Can react with strong oxidizing agents.
Conditions to avoid : None known.
Incompatible materials : Oxidizing agents
Hazardous decomposition products : No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION**Information on likely routes of exposure**

Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg
Remarks: No significant adverse effects were reported
No mortality observed at this dose.

Acute dermal toxicity : LD50 (Rat): > 2,000 mg/kg
Remarks: No significant adverse effects were reported

Components:**White mineral oil (petroleum):**

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg
Acute inhalation toxicity : LC50 (Rat): > 5 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Assessment: The substance or mixture has no acute inhalation toxicity
Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg
Assessment: The substance or mixture has no acute dermal toxicity

**Orbifloxacin / Posaconazole / Mometasone
Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
6.0	03.12.2024	439121-00019	Date of first issue: 06.01.2016

Orbifloxacin:

Acute oral toxicity	:	LD50 (Rat): > 3,000 mg/kg Remarks: No mortality observed at this dose. LD50 (Mouse): > 2,000 mg/kg Remarks: No mortality observed at this dose. LD50 (Dog): > 600 mg/kg Symptoms: Vomiting Remarks: No mortality observed at this dose.
Acute inhalation toxicity	:	Remarks: No data available
Acute dermal toxicity	:	Remarks: No data available
Acute toxicity (other routes of administration)	:	LD50 (Rat): > 200 mg/kg Application Route: Intramuscular LD50 (Mouse): 500 mg/kg Application Route: Intramuscular LD50 (Rat): 233 mg/kg Application Route: Intravenous LD50 (Mouse): 250 mg/kg Application Route: Intravenous

Posaconazole:

Acute oral toxicity	:	LD50 (Rat): > 5,000 mg/kg LD50 (Mouse): > 3,000 mg/kg
Acute dermal toxicity	:	LD50 (Rat): > 2,000 mg/kg

Mometasone:

Acute oral toxicity	:	LD50 (Rat): > 2,000 mg/kg LD50 (Mouse): > 2,000 mg/kg
Acute inhalation toxicity	:	LC50 (Rat): > 3.3 mg/l Exposure time: 4 h Test atmosphere: dust/mist Remarks: No mortality observed at this dose. LC50 (Mouse): > 3.2 mg/l Exposure time: 4 h Test atmosphere: dust/mist
Acute toxicity (other routes of administration)	:	LD50 (Rat): 300 mg/kg Application Route: Subcutaneous Symptoms: Breathing difficulties

**Orbifloxacin / Posaconazole / Mometasone
Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
6.0	03.12.2024	439121-00019	Date of first issue: 06.01.2016

Skin corrosion/irritation

Not classified based on available information.

Product:

Species	:	Rabbit
Result	:	Mild skin irritation

Components:**White mineral oil (petroleum):**

Species	:	Rabbit
Result	:	No skin irritation

Orbifloxacin:

Species	:	Rabbit
Method	:	Draize Test
Result	:	No skin irritation

Posaconazole:

Species	:	Rabbit
Result	:	No skin irritation

Mometasone:

Species	:	Rabbit
Result	:	No skin irritation

Serious eye damage/eye irritation

Causes eye irritation.

Product:

Species	:	Rabbit
Result	:	Mild eye irritation

Components:**White mineral oil (petroleum):**

Species	:	Rabbit
Result	:	No eye irritation

Orbifloxacin:

Species	:	Rabbit
Result	:	Mild eye irritation
Method	:	Draize Test

Posaconazole:

Species	:	Rabbit
Result	:	Mild eye irritation

**Orbifloxacin / Posaconazole / Mometasone
Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
6.0	03.12.2024	439121-00019	Date of first issue: 06.01.2016

Mometasone:

Species	: Rabbit
Result	: No eye irritation

Respiratory or skin sensitization**Skin sensitization**

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Product:

Test Type	: Magnusson-Kligman-Test
Routes of exposure	: Dermal
Result	: Not a skin sensitizer.

Components:**White mineral oil (petroleum):**

Test Type	: Buehler Test
Routes of exposure	: Skin contact
Species	: Guinea pig
Result	: negative

Orbifloxacin:

Test Type	: Maximization Test
Routes of exposure	: Dermal
Species	: Guinea pig
Result	: Not a skin sensitizer.

Posaconazole:

Test Type	: Magnusson-Kligman-Test
Routes of exposure	: Skin contact
Species	: Guinea pig
Result	: negative

Mometasone:

Test Type	: Maximization Test
Routes of exposure	: Dermal
Species	: Guinea pig
Assessment	: Does not cause skin sensitization.
Result	: negative
Remarks	: The results of a test on guinea pigs showed this substance to be a weak skin sensitizer.

Germ cell mutagenicity

Not classified based on available information.

**Orbifloxacin / Posaconazole / Mometasone
Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
6.0	03.12.2024	439121-00019	Date of first issue: 06.01.2016

Components:**White mineral oil (petroleum):**

Genotoxicity in vitro	:	Test Type: In vitro mammalian cell gene mutation test Result: negative
Genotoxicity in vivo	:	Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Mouse Application Route: Intraperitoneal injection Method: OECD Test Guideline 474 Result: negative Remarks: Based on data from similar materials

Orbifloxacin:

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES) Result: equivocal Test Type: Mouse Lymphoma Result: positive Test Type: Chromosomal aberration Test system: Human lymphocytes Result: positive
Genotoxicity in vivo	:	Test Type: Micronucleus test Species: Mouse Cell type: Bone marrow Application Route: Intraperitoneal injection Result: negative Test Type: unscheduled DNA synthesis assay Species: Rat Cell type: Liver cells Application Route: Oral Result: negative
Germ cell mutagenicity - Assessment	:	Weight of evidence does not support classification as a germ cell mutagen.

Posaconazole:

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES) Result: negative Test Type: Chromosomal aberration Result: negative
Genotoxicity in vivo	:	Test Type: Micronucleus test Species: Mouse Cell type: Bone marrow Application Route: Intravenous Result: negative

**Orbifloxacin / Posaconazole / Mometasone
Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
6.0	03.12.2024	439121-00019	Date of first issue: 06.01.2016

II**Mometasone:**

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES) Result: negative Test Type: Chromosomal aberration Test system: Chinese hamster lung cells Result: negative Test Type: Chromosomal aberration Test system: Chinese hamster ovary cells Result: positive Test Type: Mouse Lymphoma Result: negative
Genotoxicity in vivo	: Test Type: Micronucleus test Species: Mouse Application Route: Oral Result: negative Test Type: Chromosomal aberration Species: Rat Cell type: Bone marrow Result: negative Test Type: unscheduled DNA synthesis assay Species: Rat Cell type: Liver cells Result: negative
Germ cell mutagenicity - Assessment	: Weight of evidence does not support classification as a germ cell mutagen.

Carcinogenicity

Not classified based on available information.

Components:**White mineral oil (petroleum):**

Species	: Rat
Application Route	: Ingestion
Exposure time	: 24 Months
Result	: negative

Orbifloxacin:

Species	: Rat
Application Route	: Oral
Exposure time	: 2 Years
NOAEL	: 200 mg/kg body weight
Result	: negative

**Orbifloxacin / Posaconazole / Mometasone
Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
6.0	03.12.2024	439121-00019	Date of first issue: 06.01.2016

Species	: Mouse
Application Route	: Oral
Exposure time	: 2 Years
NOAEL	: 200 mg/kg body weight
Result	: negative

Posaconazole:

Species	: Rat
Application Route	: oral (feed)
Exposure time	: 2 Years
Result	: positive
Remarks	: The mechanism or mode of action is not relevant in humans.

Species	: Mouse
Application Route	: Oral
Exposure time	: 2 Years
Result	: positive
Remarks	: The mechanism or mode of action is not relevant in humans.

Mometasone:

Species	: Rat
Application Route	: Inhalation
Exposure time	: 2 Years
Dose	: 0.067 mg/kg body weight
Result	: negative

Species	: Mouse
Application Route	: Inhalation
Exposure time	: 19 Months
Dose	: 0.160 mg/kg body weight
Result	: negative

Reproductive toxicity

May damage the unborn child. Suspected of damaging fertility.

Components:**White mineral oil (petroleum):**

Effects on fertility	: Test Type: One-generation reproduction toxicity study Species: Rat Application Route: Skin contact Result: negative
Effects on fetal development	: Test Type: Embryo-fetal development Species: Rat Application Route: Ingestion Result: negative

Orbifloxacin:

Effects on fertility	: Test Type: Two-generation reproduction toxicity study Species: Rat
----------------------	-------------------------------------------------------------------------

**Orbifloxacin / Posaconazole / Mometasone
Formulation**

Version 6.0	Revision Date: 03.12.2024	SDS Number: 439121-00019	Date of last issue: 30.09.2023 Date of first issue: 06.01.2016
----------------	------------------------------	-----------------------------	-------------------------------------------------------------------

	Application Route: Oral General Toxicity Parent: NOAEL: 50 mg/kg body weight Early Embryonic Development: NOAEL: 50 mg/kg body weight Result: No adverse effects.
Effects on fetal development	: Test Type: Embryo-fetal development Species: Rat Application Route: Oral Embryo-fetal toxicity.: LOAEL: 333 mg/kg body weight Result: No teratogenic effects., Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses Test Type: Embryo-fetal development Species: Rabbit Application Route: Oral General Toxicity Maternal: NOAEL: 20 mg/kg body weight Embryo-fetal toxicity.: NOAEL: 60 mg/kg body weight Result: No effects on early embryonic development., Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses, Reduced maternal body weight gain. Test Type: Development Species: Dog Application Route: Oral Developmental Toxicity: LOAEL: 2.5 mg/kg body weight Result: Effects on postnatal development., Skeletal malformations.
Reproductive toxicity - Assessment	: Some evidence of adverse effects on development, based on animal experiments.

Posaconazole:

Effects on fertility	: Test Type: Fertility/early embryonic development Species: Rat, male General Toxicity Parent: NOAEL: 180 mg/kg body weight Symptoms: No effects on mating performance. Result: negative Test Type: Fertility/early embryonic development Species: Rat, female General Toxicity Parent: NOAEL: 45 mg/kg body weight Symptoms: No effects on mating performance. Result: negative
Effects on fetal development	: Test Type: Embryo-fetal development Species: Rat, female Application Route: Oral Developmental Toxicity: LOAEL: 29 mg/kg body weight Result: Fetotoxicity., Malformations were observed.

Orbifloxacin / Posaconazole / Mometasone Formulation

Version 6.0 Revision Date: 03.12.2024 SDS Number: 439121-00019 Date of last issue: 30.09.2023
Date of first issue: 06.01.2016

Test Type: Embryo-fetal development
Species: Rabbit, female
Developmental Toxicity: LOAEL: 40 mg/kg body weight
Result: Fetotoxicity.

Reproductive toxicity - Assessment : Some evidence of adverse effects on development, based on animal experiments.

Mometasone:

Effects on fertility : Test Type: Fertility
Species: Rat
Application Route: Subcutaneous
Fertility: NOAEL: 0.015 mg/kg body weight
Symptoms: Reduced embryonic survival, Reduced fetal weight.
Result: No effects on fertility., Effect on reproduction capacity.

Effects on fetal development : Test Type: Embryo-fetal development
Species: Mouse
Application Route: Subcutaneous
Embryo-fetal toxicity.: LOAEL: 0.06 mg/kg body weight
Result: Embryotoxic effects., Teratogenicity and developmental toxicity

Test Type: Embryo-fetal development
Species: Rat
Application Route: Dermal
Embryo-fetal toxicity.: LOAEL: 0.3 mg/kg body weight
Result: Embryo-fetal toxicity.

Test Type: Embryo-fetal development
Species: Rabbit
Application Route: Dermal
Embryo-fetal toxicity.: LOAEL: 0.15 mg/kg body weight
Result: Embryo-fetal toxicity., Malformations were observed.

Test Type: Embryo-fetal development
Species: Rat
Application Route: Subcutaneous
Embryo-fetal toxicity.: LOAEL: 0.15 mg/kg body weight
Result: Effects on newborn.

Test Type: Embryo-fetal development
Species: Rabbit
Application Route: Oral
Embryo-fetal toxicity.: LOAEL: 0.7 mg/kg body weight
Result: Embryo-fetal toxicity., Malformations were observed.

Reproductive toxicity - Assessment : Clear evidence of adverse effects on development, based on animal experiments., Some evidence of adverse effects on sexual function and fertility, based on animal experiments.

**Orbifloxacin / Posaconazole / Mometasone
Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
6.0	03.12.2024	439121-00019	Date of first issue: 06.01.2016

STOT-single exposure

Not classified based on available information.

Components:**Mometasone:**

Remarks	: Based on available data, the classification criteria are not met.
---------	---------------------------------------------------------------------

STOT-repeated exposure

Not classified based on available information.

Components:**Posaconazole:**

Routes of exposure	: Ingestion
Target Organs	: Adrenal gland, Bone marrow, Kidney, Liver, Reproductive organs, Nervous system
Assessment	: Causes damage to organs through prolonged or repeated exposure.

Mometasone:

Routes of exposure	: inhalation (dust/mist/fume)
Target Organs	: Immune system, Liver, Kidney, Skin
Assessment	: May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity**Components:****White mineral oil (petroleum):**

Species	: Rat
LOAEL	: 160 mg/kg
Application Route	: Ingestion
Exposure time	: 90 Days

Species	: Rat
LOAEL	: >= 1 mg/l
Application Route	: inhalation (dust/mist/fume)
Exposure time	: 4 Weeks
Method	: OECD Test Guideline 412

Orbifloxacin:

Species	: Rat
NOAEL	: 20 mg/kg
LOAEL	: 80 mg/kg
Application Route	: Oral
Exposure time	: 3 Months
Target Organs	: Testis, Liver, Kidney, spleen

Species	: Mouse
---------	---------

**Orbifloxacin / Posaconazole / Mometasone
Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
6.0	03.12.2024	439121-00019	Date of first issue: 06.01.2016

NOAEL	: 80 mg/kg
LOAEL	: 250 mg/kg
Application Route	: Oral
Exposure time	: 3 Months

Species	: Juvenile dog
NOAEL	: 50 mg/kg
LOAEL	: 250 mg/kg
Application Route	: Oral
Exposure time	: 14 Days
Target Organs	: Heart, Bone
Symptoms	: Gastrointestinal disturbance
Remarks	: mortality observed

Species	: Juvenile dog
NOAEL	: 2 mg/kg
LOAEL	: 3 mg/kg
Application Route	: Oral
Exposure time	: 90 Days
Target Organs	: Bone
Remarks	: No significant adverse effects were reported

Species	: Dog
NOAEL	: 37.5 mg/kg
Application Route	: Oral
Exposure time	: 30 Days

Species	: Cat
NOAEL	: 7.5 mg/kg
LOAEL	: 22.5 mg/kg
Application Route	: Oral
Exposure time	: 1 Months
Symptoms	: Gastrointestinal disturbance

Posaconazole:

Species	: Rat, female
LOAEL	: 5 mg/kg
Application Route	: Oral
Exposure time	: 6 Months
Target Organs	: Adrenal gland, Lungs, Heart, Liver, spleen, Kidney, Ovary

Species	: Dog
LOAEL	: 3 mg/kg
Application Route	: Oral
Exposure time	: 392 Days
Target Organs	: Lungs, Liver, Brain, small intestine, Adrenal gland, Spinal cord, lymphoid tissue

Species	: Monkey
LOAEL	: 15 mg/kg
Application Route	: Oral
Exposure time	: 1 Months
Target Organs	: Bone marrow, Adrenal gland, Lymph nodes, Blood

**Orbifloxacin / Posaconazole / Mometasone
Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
6.0	03.12.2024	439121-00019	Date of first issue: 06.01.2016

Species	: Dog
LOAEL	: 3 mg/kg
Application Route	: Oral
Exposure time	: 56 Weeks
Target Organs	: Adrenal gland, Bone marrow, Kidney, Nervous system, spleen, thymus gland, Testis, lymphoid tissue

Species	: Monkey
LOAEL	: 180 mg/kg
Application Route	: Oral
Exposure time	: 12 Months
Target Organs	: Blood, Gastrointestinal tract, spleen

Species	: Monkey
LOAEL	: 8 mg/kg
Application Route	: Intravenous
Exposure time	: 1 Months
Target Organs	: Cardio-vascular system, Lungs, Adrenal gland, Blood

Mometasone:

Species	: Rat
NOAEL	: 0.005 mg/kg
LOAEL	: 0.3 mg/kg
Application Route	: Oral
Exposure time	: 30 d
Target Organs	: Lymph nodes, Liver, Adrenal gland, Skin, thymus gland

Species	: Dog
LOAEL	: 0.5 mg/kg
Application Route	: Oral
Exposure time	: 30 d
Target Organs	: Lymph nodes, Liver, Adrenal gland, Skin, thymus gland

Species	: Rat
NOAEL	: 0.00013 mg/l
Application Route	: inhalation (dust/mist/fume)
Exposure time	: 90 d
Target Organs	: Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow, Kidney, Liver, thymus gland

Species	: Dog
NOAEL	: 0.0005 mg/l
Application Route	: inhalation (dust/mist/fume)
Exposure time	: 90 d
Target Organs	: Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow, Kidney, thymus gland, Liver

Aspiration toxicity

Not classified based on available information.

**Orbifloxacin / Posaconazole / Mometasone
Formulation**

Version 6.0	Revision Date: 03.12.2024	SDS Number: 439121-00019	Date of last issue: 30.09.2023 Date of first issue: 06.01.2016
----------------	------------------------------	-----------------------------	-------------------------------------------------------------------

Components:**Mometasone:**

|| Not applicable

Experience with human exposure**Components:****Orbifloxacin:**

Ingestion	: Symptoms: central nervous system effects, Gastrointestinal disturbance, liver function change, anaphylaxis, Rash Remarks: May cause photosensitization.
-----------	--------------------------------------------------------------------------------------------------------------------------------------------------------------

Posaconazole:

Ingestion	: Symptoms: Cough, Headache, Nausea, Vomiting, Fever, Liver effects, Rash, pruritis, Diarrhea, hypertension, neutropenia, electrolyte imbalance
-----------	-------------------------------------------------------------------------------------------------------------------------------------------------

Mometasone:

Inhalation	: Symptoms: allergic rhinitis, Headache, pharyngitis, upper respiratory tract infection, sinusitis, oral candidiasis, Back pain, musculoskeletal pain, immune system effects, indigestion
Skin contact	: Symptoms: Dermatitis, Itching

Further information**Components:****Mometasone:**

Remarks	: Dermal absorption possible
---------	------------------------------

SECTION 12. ECOLOGICAL INFORMATION**Ecotoxicity****Components:****White mineral oil (petroleum):**

Toxicity to fish	: LC50 (Oncorhynchus mykiss (rainbow trout)): > 100 mg/l Exposure time: 96 h Method: OECD Test Guideline 203
Toxicity to daphnia and other aquatic invertebrates	: EC50 (Daphnia magna (Water flea)): > 100 mg/l Exposure time: 48 h Method: OECD Test Guideline 202
Toxicity to algae/aquatic plants	: NOEC (Pseudokirchneriella subcapitata (green algae)): 100 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
Toxicity to fish (Chronic tox-	: NOEC (Oncorhynchus mykiss (rainbow trout)): 1,000 mg/l

Orbifloxacin / Posaconazole / Mometasone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
6.0	03.12.2024	439121-00019	Date of first issue: 06.01.2016

icity)	Exposure time: 28 d
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)	: NOEC (Daphnia magna (Water flea)): 1,000 mg/l Exposure time: 21 d
Posaconazole:	
Toxicity to fish	: LC50 (Oncorhynchus mykiss (rainbow trout)): > 0.95 mg/l Exposure time: 96 h Method: OECD Test Guideline 203 Remarks: No toxicity at the limit of solubility.
Toxicity to daphnia and other aquatic invertebrates	: EC50 (Daphnia magna (Water flea)): 0.276 mg/l Exposure time: 48 h Method: OECD Test Guideline 202
Toxicity to algae/aquatic plants	: EC50 (Pseudokirchneriella subcapitata (green algae)): > 0.509 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 NOEC (Pseudokirchneriella subcapitata (green algae)): 0.041 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
Toxicity to fish (Chronic toxicity)	: NOEC (Pimephales promelas (fathead minnow)): 0.206 mg/l Exposure time: 33 d Method: OECD Test Guideline 210
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)	: NOEC (Daphnia magna (Water flea)): 0.244 mg/l Exposure time: 21 d Method: OECD Test Guideline 211 Remarks: No toxicity at the limit of solubility.
Toxicity to microorganisms	: EC50 (Natural microorganism): > 1,000 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209
Mometasone:	
Toxicity to fish	: LC50 (Menidia beryllina (Silverside)): 0.11 mg/l Exposure time: 96 h Remarks: No toxicity at the limit of solubility. LC50 (Cyprinodon variegatus (sheepshead minnow)): > 5 mg/l Exposure time: 7 d Remarks: No toxicity at the limit of solubility.
Toxicity to daphnia and other aquatic invertebrates	: EC50 (Daphnia magna (Water flea)): > 5 mg/l Exposure time: 48 h Method: OECD Test Guideline 202 Remarks: No toxicity at the limit of solubility.

**Orbifloxacin / Posaconazole / Mometasone
Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
6.0	03.12.2024	439121-00019	Date of first issue: 06.01.2016

		EC50 (Americamysis): > 5 mg/l Exposure time: 96 h Method: US-EPA OPPTS 850.1035 Remarks: No toxicity at the limit of solubility.
Toxicity to algae/aquatic plants	:	EC50 (Pseudokirchneriella subcapitata (green algae)): > 3.2 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 Remarks: No toxicity at the limit of solubility.
Toxicity to fish (Chronic toxicity)	:	NOEC (Pimephales promelas (fathead minnow)): 0.00014 mg/l Exposure time: 32 d Method: OECD Test Guideline 210
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)	:	NOEC (Daphnia magna (Water flea)): 0.34 mg/l Exposure time: 21 d Method: OECD Test Guideline 211 Remarks: No toxicity at the limit of solubility.
Toxicity to microorganisms	:	EC50: > 1,000 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209 Remarks: No toxicity at the limit of solubility.
		NOEC: 1,000 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209 Remarks: No toxicity at the limit of solubility.

Persistence and degradability
Components:
White mineral oil (petroleum):

Biodegradability	:	Result: Not readily biodegradable. Biodegradation: 31 % Exposure time: 28 d
------------------	---	-----------------------------------------------------------------------------------

Posaconazole:

Biodegradability	:	Result: Not readily biodegradable. Biodegradation: 50 % Exposure time: 28 h Method: OECD Test Guideline 314
Stability in water	:	Degradation half life (DT50): > 30 d Method: OECD Test Guideline 111

**Orbifloxacin / Posaconazole / Mometasone
Formulation**

Version	Revision Date:	SDS Number:	Date of last issue:
6.0	03.12.2024	439121-00019	30.09.2023
			Date of first issue: 06.01.2016

Mometasone:

Biodegradability	: Result: Not readily biodegradable. Biodegradation: 50 % Exposure time: 28 d Method: OECD Test Guideline 314
Stability in water	: Hydrolysis: 50 %(12 d) Method: OECD Test Guideline 111

Bioaccumulative potential**Components:****Posaconazole:**

Bioaccumulation	: Species: Lepomis macrochirus (Bluegill sunfish) Bioconcentration factor (BCF): 20 Method: OECD Test Guideline 305
Partition coefficient: n-octanol/water	: log Pow: 4.15

Mometasone:

Bioaccumulation	: Species: Lepomis macrochirus (Bluegill sunfish) Bioconcentration factor (BCF): 107.1 Method: OECD Test Guideline 305
Partition coefficient: n-octanol/water	: log Pow: 4.68

Mobility in soil**Components:****Posaconazole:**

Distribution among environmental compartments	: log Koc: 5.52
-----------------------------------------------	-----------------

Mometasone:

Distribution among environmental compartments	: log Koc: 4.02
-----------------------------------------------	-----------------

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS**Disposal methods**

Waste from residues	: Do not dispose of waste into sewer. Dispose of in accordance with local regulations.
Contaminated packaging	: Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

**Orbifloxacin / Posaconazole / Mometasone
Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
6.0	03.12.2024	439121-00019	Date of first issue: 06.01.2016

SECTION 14. TRANSPORT INFORMATION**International Regulations****UNRTDG**

UN number	: UN 3082
Proper shipping name	: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (Mometasone, Posaconazole)
Class	: 9
Packing group	: III
Labels	: 9
Environmentally hazardous	: yes

IATA-DGR

UN/ID No.	: UN 3082
Proper shipping name	: Environmentally hazardous substance, liquid, n.o.s. (Mometasone, Posaconazole)
Class	: 9
Packing group	: III
Labels	: Miscellaneous
Packing instruction (cargo aircraft)	: 964
Packing instruction (passenger aircraft)	: 964
Environmentally hazardous	: yes

IMDG-Code

UN number	: UN 3082
Proper shipping name	: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (Mometasone, Posaconazole)
Class	: 9
Packing group	: III
Labels	: 9
EmS Code	: F-A, S-F
Marine pollutant	: yes

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation**NOM-002-SCT**

UN number	: UN 3082
Proper shipping name	: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (Mometasone, Posaconazole)
Class	: 9
Packing group	: III
Labels	: 9

Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data

**Orbifloxacin / Posaconazole / Mometasone
Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
6.0	03.12.2024	439121-00019	Date of first issue: 06.01.2016

Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

SECTION 15. REGULATORY INFORMATION**Safety, health and environmental regulations/legislation specific for the substance or mixture**

Federal Law for the control of chemical precursors, : Not applicable
essential chemical products and machinery for
producing capsules, tablets and pills.

The ingredients of this product are reported in the following inventories:

AICS	: not determined
DSL	: not determined
IECSC	: not determined

SECTION 16. OTHER INFORMATION

Revision Date	: 03.12.2024
Date format	: dd.mm.yyyy

Full text of other abbreviations

ACGIH	: USA. ACGIH Threshold Limit Values (TLV)
NOM-010-STPS-2014	: Mexico. Norm NOM-010-STPS-2014 on Chemicals Polluting the Work Environment - Identification, Assessment and Control - Appendix 1 Occupational Exposure Limits
ACGIH / TWA	: 8-hour, time-weighted average
NOM-010-STPS-2014 / VLE-	: Time weighted average limit value
PPT	

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect

**Orbifloxacin / Posaconazole / Mometasone
Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
6.0	03.12.2024	439121-00019	Date of first issue: 06.01.2016

Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information is considered as correct, but not exhaustive, and will be used only as a guide, which is based in the current knowledge of the substance or mixture, and is applicable to proper safety precautions for the product.

MX / Z8